This study examines to what extent modulating NO/sGC pathway attenuates the cardiovascular, renal, and metabolic effects of a prolonged HFD in rats with ARDev whose hypertension and deterioration of renal function are associated with a decrease in eNOS bioavailability and increases in oxidative and inflammatory markers (2, 4). The gene discussed is SGCB; the disease is hypertensive disorder.